LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Femasys Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERFEMY
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / FEMY COVERAGE

What’s moving Femasys Inc. now

Current reporting with the operating signal separated from the noise.

01
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Investors are testing whether Femasys Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Investors are testing whether Femasys Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Investors are testing whether Femasys Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

The story matters when it changes Femasys Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

The development tests whether Femasys Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
06
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

The story matters when it changes Femasys Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer

Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer

The story matters when it changes Femasys Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest FEMY filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-08 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-31 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-24 · Period 2026-06-24SEC ↗8-KMaterial company eventFiled 2026-06-24 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-06-05 · Period 2026-06-05SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2026-06-24SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-04SEC ↗
EARNINGS / QUARTERLY TRACKER

Femasys Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.